Generex erhält Aufträge! - 500 Beiträge pro Seite

[holle72]

Hier die Meldung:

Press Release Source: Generex Biotechnology

Generex Biotechnology Announces Expansion of Glucose RapidSpray(TM) Distribution
Tuesday October 10, 8:00 am ET

Company Fills Purchase Orders From Additional Retail Pharmacies

TORONTO--(MARKET WIRE)--Oct 10, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that it has filled several purchase orders from additional retail pharmacies for Glucose RapidSpray, its new over-the-counter glucose oral spray product.
Generex has filled orders for Meijer, Inc., Kerr Drug, Inc., Hy-Vee, Inc., and Fruth Pharmacy, Inc.

Additional information on the product may be found at www.GlucoseRapidSpray.com.

ADVERTISEMENT

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


Contact:
Contacts:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone]
or [phone]

Andrew Hellman
CEOcast, Inc.
Phone: [phone]

Dolores Naney
Rubenstein Public Relations
Phone: [phone]
Email Contact

Source: Generex Biotechnology


News:
GNBT -- Generex Biotechnology Corp.
Com ($0.001)

COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
www.streetinvesting.com: Global Market Perspective Progressive Review on Generex Biotechnology Corporation

Oct 10, 2006 (M2 PRESSWIRE via COMTEX) -- Streetinvesting.com is the author of this release. This release is a result of our current concentration on Generex Biotechnology Corporation (NASDAQ:GNBT) and their latest corporate developments and market performance. Our goal is to help investors seek a diversified portfolio by introducing techniques to help grasp a better understanding and concept of the market and the daily activities that a public company experiences. The first stage of this process is to continually track Generex Biotechnology Corporation and use the information that we may find to our advantage. To learn more and become part of the acclaimed online financial newsletter community, visit www.streetinvesting.com for a complimentary subscription.

Generex Biotechnology Corporation was up 20.77% come market closure Monday. Investors also saw approximately 10,820,620 shares having traded hands come the toll of the day\'s closing bell.

The American Markets exhibited a slight gain Monday, with the Dow Jones industrial average briefly touching a new intraday trading high. Canadian markets were closed however, as traders north of the Boarder enjoyed Thanksgiving dinner.

Wall Street started the session on a negative note after North Korea announced it had set off an atomic weapon underground. To the surprise of many though the markets were quick to recover and investor sentiments were rejuvenated as the day progressed.

Contributing to the upbeat sentiment of some were reports that OPEC was near announcing its first output cut in two years. Although this came as good news for a few, others were not as enthusiastic. Nevertheless, stocks had edged higher by early afternoon.

According to preliminary calculations, the Dow Jones industrial average rose 7.60, or 0.06 percent, to 11,857.81. Broader stock indicators also progressed, with the Standard & Poor\'s 500 index rising 1.08, or 0.08 percent, to 1,350.66, and the Nasdaq composite index rising 11.78, or 0.51 percent, to 2,311.77.

Generex Biotechnology Corporation stood out in the crowd Monday and amidst the day\'s overall success secured...

Please visit www.streetinvesting.com for a complimentary subscription to access this issuance and other related in-depth articles. Please note that membership does not require credit card information nor does it require a commitment to our service.

We have initiated this news release as a tool to keep investors informed about the market. The information contained herein comes from an unbiased perspective and we do not have a vested interest in the companies mentioned in this release. Becoming a member to www.streetinvesting.com will give you access to all the on-going information and investment news that we come across.

Investors wishing to seek a different approach to their investment theories and concepts and to be informed of unique investment opportunities should also visit www.streetinvesting.com for a free membership.

About Street Investing

[liftboi]

So langsam wird mir klar, woher die Kurssprünge kommen. Ist das eine nachhaltige Sache ? Was meint ihr ?

Gruß liftboi

[holle72]

Ich sag, das ist erst der Anfang. Wenn das Medikament sich erstmal etabliert hat, werden weitere Aufträge zwangsläufig folgen. Und bald ist wieder Vogel-Grippe-Zeit!!! Das Thema ist noch längst nicht vom Tisch, im Gegenteil...das wird dieses Jahr erst richtig ernst.